How This Works
Tesamorelin is a synthetic 44‑amino‑acid GHRH analog that stimulates pituitary GH release[3]. Ipamorelin is a pentapeptide ghrelin mimetic that acts on the GHS‑R1a receptor, selectively stimulating GH secretion without significantly affecting cortisol, prolactin, or ACTH[4][7]. Combined GHRH + GHRP/ghrelin‑mimetic preparation produces synergistic, amplified GH pulses compared to either agent alone[1][2]. Human pharmacokinetic studies show ipamorelin achieves peak GH release approximately 40 minutes post‑dose[8].
References
PMC — The Safety and Efficacy of Growth Hormone Secretagogues
— GHRH + GHRP synergy; dual pathway GH stimulation mechanisms
Endocrine Reviews — Growth Hormone Secretagogues
— Synergistic amplification of GH release with combined GHRH and ghrelin mimetics
NCBI LiverTox — Tesamorelin
— Synthetic GHRH analog; recommended dose 2 mg SC daily for HIV lipodystrophy
PubMed — Ipamorelin, the first selective growth hormone secretagogue
— High GH potency and selectivity; no cortisol/ACTH effect
FDA Egrifta (tesamorelin) Label
— SC abdomen measurement; rotate sites; storage and reconstitution guidance
CDC — Vaccine Preparation: Measurement
— handling reference (45° angle, pinch skin, no aspiration)
European Journal of Endocrinology — Ipamorelin GH selectivity
— Potent and specific GH release without affecting cortisol, prolactin, or FSH/LH
View Source
PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin
— Human GH release peaked ~0.67 h post-dose
JAMA — Tesamorelin for Abdominal Fat in HIV
— Phase 3 trials demonstrating visceral fat reduction with tesamorelin
CDC — Vaccine Preparation During
— General route guidance (angle/site)
NCBI Bookshelf — Best Practices for Measurement
— Asepsis, preparation, and preparation guidance
PMC — Drug Measurement Review
— Pharmacologic considerations of the route
Drugs — Tesamorelin: A Review
— Comprehensive review of tesamorelin pharmacology and clinical use
